Healthy Skepticism Library item: 6391

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lipinski CA.
The anti-intellectual effects of intellectual property.
Curr Opin Chem Biol 2006 Aug 01; 10:(4):380-3
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRX-4KBX4TV-1&_coverDate=08%2F31%2F2006&_alid=479530075&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6246&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=5efdf8d9227422f5ff8f02f0368bf86f

Abstract:

Intellectual property considerations decrease research productivity in subtle and unanticipated ways. Chemical probe exchange between Pharma and academia is hindered by academic IP interests. These are perceived as a subtle nuisance by the academic researcher. Novel ligands for oral targets are historically few and numbers of economically attractive oral drug targets are limited. Economically speculative targets lie in the academic domain but the medicinal chemistry to explore these in a drug discovery sense lies in Pharma and cooperation between the two is hindered by very different academic and Pharma views on chemical quality. Tools and probes for academic target validation can accommodate looser chemical quality criteria as opposed to the very strict chemical quality criteria required in Pharma drug discovery.

Keywords:
Academies and Institutes* Drug Design* Drug Evaluation, Preclinical/economics* Drug Industry* Intellectual Property*